379 related articles for article (PubMed ID: 28331317)
1. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects.
Song Z; Lin Y; Zhang X; Feng C; Lu Y; Gao Y; Dong C
Int J Nanomedicine; 2017; 12():1941-1958. PubMed ID: 28331317
[TBL] [Abstract][Full Text] [Related]
2. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
3. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats.
Chen Z; Deng J; Zhao Y; Tao T
Int J Nanomedicine; 2012; 7():3803-11. PubMed ID: 22888235
[TBL] [Abstract][Full Text] [Related]
4. cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo.
Zhu Y; Zhang J; Meng F; Deng C; Cheng R; Feijen J; Zhong Z
J Control Release; 2016 Jul; 233():29-38. PubMed ID: 27178807
[TBL] [Abstract][Full Text] [Related]
5. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
[TBL] [Abstract][Full Text] [Related]
6. Enhanced uptake and improved anti-tumor efficacy of doxorubicin loaded fibrin gel with liposomal apatinib in colorectal cancer.
Hu Y; Wu C; Zhu C; Fu Q; Guo J; Deng L; He Y; Yang D; Cheng Y; Gao X
Int J Pharm; 2018 Dec; 552(1-2):319-327. PubMed ID: 30308269
[TBL] [Abstract][Full Text] [Related]
7. Targeted glioma chemotherapy by cyclic RGD peptide-functionalized reversibly core-crosslinked multifunctional poly(ethylene glycol)-b-poly(ε-caprolactone) micelles.
Fang Y; Jiang Y; Zou Y; Meng F; Zhang J; Deng C; Sun H; Zhong Z
Acta Biomater; 2017 Mar; 50():396-406. PubMed ID: 28065871
[TBL] [Abstract][Full Text] [Related]
8. Anti-Colorectal Cancer Effect via Application of Polyethylene Glycol Modified Liposomal Apatinib.
Hu Y; Zhou P; Lin Y; Yang D; Wang B
J Biomed Nanotechnol; 2019 Jun; 15(6):1256-1266. PubMed ID: 31072433
[TBL] [Abstract][Full Text] [Related]
9. Cyclic RGD-Decorated Liposomal Gossypol AT-101 Targeting for Enhanced Antitumor Effect.
Liu H; Zhang R; Zhang D; Zhang C; Zhang Z; Fu X; Luo Y; Chen S; Wu A; Zeng W; Qu K; Zhang H; Wang S; Shi H
Int J Nanomedicine; 2022; 17():227-244. PubMed ID: 35068931
[TBL] [Abstract][Full Text] [Related]
10. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
[TBL] [Abstract][Full Text] [Related]
11. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.
Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY
Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336
[TBL] [Abstract][Full Text] [Related]
12. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
[TBL] [Abstract][Full Text] [Related]
13. Cyclo(RGD)-Decorated Reduction-Responsive Nanogels Mediate Targeted Chemotherapy of Integrin Overexpressing Human Glioblastoma In Vivo.
Chen W; Zou Y; Zhong Z; Haag R
Small; 2017 Feb; 13(6):. PubMed ID: 27865044
[TBL] [Abstract][Full Text] [Related]
14. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
Yamamoto S; Sakurai Y; Harashima H
Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
[TBL] [Abstract][Full Text] [Related]
15. α
Zhong P; Meng H; Qiu J; Zhang J; Sun H; Cheng R; Zhong Z
J Control Release; 2017 Aug; 259():176-186. PubMed ID: 27986551
[TBL] [Abstract][Full Text] [Related]
16. Integrin α
Fu S; Zhao Y; Sun J; Yang T; Zhi D; Zhang E; Zhong F; Zhen Y; Zhang S; Zhang S
Colloids Surf B Biointerfaces; 2021 May; 201():111623. PubMed ID: 33636597
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
18. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
[TBL] [Abstract][Full Text] [Related]
19. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
20. Cyclic RGD-conjugated Pluronic
Lim C; Moon J; Sim T; Hoang NH; Won WR; Lee ES; Youn YS; Choi HG; Oh K; Oh KT
Int J Nanomedicine; 2018; 13():4627-4639. PubMed ID: 30127610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]